Re-appointment of Dr.Pankaj Shah (DIN:02836324) as Managing Director & CEO subject to the members approval for a period of three (3) years i.e from August 01, 2025 to July 31, 2028
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Aspira Pathlab & Diagnostics, at its meeting on May 16, 2025, approved the re-appointment of Dr. Pankaj Shah (DIN: 02836324) as Managing Director & CEO for a fresh term of three years, from August 01, 2025 to July 31, 2028. His current term is expiring on July 31, 2025, and the re-appointment is subject to shareholder approval. Dr. Shah has over 43 years of experience in pathology and has been with the company as its guiding force. He is not related to any other Director or KMP and is not debarred from holding office by any regulator.
This is a continuity announcement — Dr. Shah remains at the helm, providing leadership stability. No material change in strategy or governance is expected, and the stock price is unlikely to move meaningfully on this news.